Zofran (Ondasetron): Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
[[Category:Antiemetics]] | [[Category:Antiemetics]] | ||
[[Category:5-HT3]] | [[Category:5-HT3]] | ||
{{Infobox drug| | {{Infobox drug|elimination_half-life=444}} | ||
==Route of administration== | ==Route of administration== | ||
Revision as of 20:13, 16 May 2023
Zofran (Ondasetron)
| elimination half-life: | 444 |
|---|
Route of administration
- Intramuscular: Injection
Dose
For anesthesia-related nausea and vomiting:
- Adult:
* Oral: 16 mg before anesthesia induction * Intravenous: 4 mg before anesthesia induction or immediately before/during/after surgery
- Pediatric:
* Oral: 4 mg for children aged 4-11 years, 30-60 minutes before surgery * Intravenous: 0.1 mg/kg (up to 4 mg) for children aged 1 month-12 years, immediately before/during/after surgery
Half-life
- The elimination half-life of ondansetron is approximately 3-6 hours.
Expected time to work
- Oral: Onset of action is approximately 30 minutes to 2 hours.
- Intravenous: Onset of action is approximately 5-30 minutes.
Use in anesthesia
Zofran is commonly used in anesthesia to:
- Prevent postoperative nausea and vomiting (PONV)
- Prevent nausea and vomiting induced by chemotherapy
- Prevent nausea and vomiting associated with radiation therapy
Side effects
- Headache
- Fatigue
- Constipation
- Diarrhea
- Dizziness
Contraindications
- Hypersensitivity to ondansetron or any component of the formulation
- Concomitant use with apomorphine
- Patients with congenital long QT syndrome
Drug interactions
- Serotonin syndrome risk may increase when combined with other serotonergic agents (e.g., SSRIs, SNRIs, TCAs, MAOIs, triptans)
References